Oncology Institute (NASDAQ:TOI) Insider Yale Podnos Sells 23,451 Shares

The Oncology Institute, Inc. (NASDAQ:TOI) insider Yale Podnos sold 23,451 shares of Oncology Institute stock in a transaction on Monday, June 8th. The shares were sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the transaction, the insider owned 259,527 shares in the company, valued at approximately $1,396,255.26. This represents a 8.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oncology Institute Trading Down 2.2%

Shares of TOI traded down $0.11 during mid-day trading on Tuesday, hitting $4.96. 1,749,711 shares of the company’s stock were exchanged, compared to its average volume of 1,864,511. The Oncology Institute, Inc. has a fifty-two week low of $2.02 and a fifty-two week high of $5.57. The business’s 50 day moving average is $3.86 and its two-hundred day moving average is $3.41. The firm has a market capitalization of $490.25 million, a P/E ratio of -13.41 and a beta of 0.37.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.05. The company had revenue of $147.44 million during the quarter, compared to analyst estimates of $142.10 million. On average, equities research analysts forecast that The Oncology Institute, Inc. will post -0.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. BTIG Research increased their price target on Oncology Institute from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. Finally, B. Riley Financial lifted their target price on shares of Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.25.

Institutional Trading of Oncology Institute

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Oncology Institute by 6.2% in the third quarter. Vanguard Group Inc. now owns 4,545,245 shares of the company’s stock worth $15,863,000 after acquiring an additional 264,358 shares in the last quarter. CenterBook Partners LP boosted its position in shares of Oncology Institute by 12.0% during the 4th quarter. CenterBook Partners LP now owns 3,029,312 shares of the company’s stock worth $10,784,000 after purchasing an additional 324,662 shares in the last quarter. Kanen Wealth Management LLC grew its stake in shares of Oncology Institute by 61.6% during the 4th quarter. Kanen Wealth Management LLC now owns 2,976,144 shares of the company’s stock worth $10,712,000 after purchasing an additional 1,134,043 shares during the period. Balyasny Asset Management L.P. grew its stake in shares of Oncology Institute by 17.3% during the 2nd quarter. Balyasny Asset Management L.P. now owns 2,518,337 shares of the company’s stock worth $5,163,000 after purchasing an additional 371,005 shares during the period. Finally, Josh Arnold Investment Consultant LLC increased its holdings in shares of Oncology Institute by 1,104.3% in the 4th quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company’s stock valued at $8,757,000 after purchasing an additional 2,255,559 shares in the last quarter. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.